Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

In comparison, at its current levels of around $195, AbbVie stock trades at 18x expected 2024 earnings of $10.88 per share. This compares with the 12x average P/E multiple for ABBV seen over the last ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Shares of AbbVie Inc. ABBV inched 0.35% higher to $193.62 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 ...

AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 – jumping from levels of $90 then to around $195 now – vs. an increase of about 50% for the S&P 500 over this ...

AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart below.

and expect AbbVie to continue to deliver long-term shareholder value. Analyst’s Disclosure: I/we have a beneficial long position in the shares of ROIV either through stock ownership, options ...

Photo: Uwe Anspach/dpa (Photo by Uwe Anspach/picture alliance via Getty Images) AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 - jumping from levels of $90 then ...